Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Etoposide 78Carboplatin 67Cisplatin 46durvalumab 26Topotecan 26atezolizumab 20Radiotherapy 19Irinotecan 19Paclitaxel 17anlotinib 16apatinib 15Nivolumab 15Drug Therapy 12pembrolizumab 9Platinum 9toripalimab 8tislelizumab 8Gemcitabine 8Bevacizumab 8Temozolomide 7Radiosurgery 7PM 01183 7Ipilimumab 7Pemetrexed 6Docetaxel 6Albumin-Bound Paclitaxel 6olaparib 5amrubicin 5Sunitinib 5surufatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Small Cell Lung Carcinoma × 7-hydroxystaurosporine × Clear all
NCT00098956 2018-07-23

7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 9 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡